<SEC-DOCUMENT>0001551152-24-000016.txt : 20240426
<SEC-HEADER>0001551152-24-000016.hdr.sgml : 20240426
<ACCEPTANCE-DATETIME>20240426074316
ACCESSION NUMBER:		0001551152-24-000016
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240426
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240426
DATE AS OF CHANGE:		20240426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AbbVie Inc.
		CENTRAL INDEX KEY:			0001551152
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				320375147
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35565
		FILM NUMBER:		24878736

	BUSINESS ADDRESS:	
		STREET 1:		1 NORTH WAUKEGAN ROAD
		CITY:			NORTH CHICAGO
		STATE:			IL
		ZIP:			60064
		BUSINESS PHONE:		(847) 932-7900

	MAIL ADDRESS:	
		STREET 1:		1 NORTH WAUKEGAN ROAD
		CITY:			NORTH CHICAGO
		STATE:			IL
		ZIP:			60064
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>abbv-20240426.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:027f36f8-6174-473b-960c-e3409d885536,g:5e3f1b59-dc6f-431a-ad79-5b605b3de4ca,d:5cef27efbe594eca9d77b92c0c2fdd80-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:abbv="http://www.abbvie.com/20240426" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>abbv-20240426</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-45">0001551152</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-46">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="abbv-20240426.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-26</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-26</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XCHI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-26</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.375SeniorNotesDue2024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-26</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1250SeniorNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-26</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec0.750SeniorNotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-26</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2.125SeniorNotesdue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-26</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2625SeniorNotesDue2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-26</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2125SeniorNotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-26</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001551152</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.250SeniorNotesdue2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-26</xbrli:startDate><xbrli:endDate>2024-04-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5cef27efbe594eca9d77b92c0c2fdd80_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;_____________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160; </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of the</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Securities Exchange Act of 1934</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">April 26, 2024</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">ABBVIE INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:29.793%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.939%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.942%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-35565</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">32-0375147</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other Jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(IRS Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;_____________________________________________________</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1 North Waukegan Road</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">North Chicago</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Illinois</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">60064-6400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)(Zip Code)</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160; </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code:&#160; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">847</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">932-7900</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:29.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.975%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.714%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.922%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading&#160;Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-17"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-18">Common Stock, $0.01 Par Value</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-19"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-20">ABBV</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-21">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-22">Chicago Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:Security12bTitle" id="f-23">1.375% Senior Notes due 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:TradingSymbol" id="f-24">ABBV24</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-25">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:Security12bTitle" id="f-26">1.250% Senior Notes due 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:TradingSymbol" id="f-27">ABBV24B</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-28">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:Security12bTitle" id="f-29">0.750% Senior Notes due 2027</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:TradingSymbol" id="f-30">ABBV27</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-6" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-31">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-7" name="dei:Security12bTitle" id="f-32">2.125% Senior Notes due 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-7" name="dei:TradingSymbol" id="f-33">ABBV28</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-7" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-34">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-8" name="dei:Security12bTitle" id="f-35">2.625% Senior Notes due 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-8" name="dei:TradingSymbol" id="f-36">ABBV28B</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-8" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-37">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-9" name="dei:Security12bTitle" id="f-38">2.125% Senior Notes due 2029</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-9" name="dei:TradingSymbol" id="f-39">ABBV29</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-9" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-40">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-10" name="dei:Security12bTitle" id="f-41">1.250% Senior Notes due 2031</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-10" name="dei:TradingSymbol" id="f-42">ABBV31</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-10" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-43">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-44">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5cef27efbe594eca9d77b92c0c2fdd80_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 2.02&#160;&#160;Results of Operations and Financial Condition</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April&#160;26, 2024, AbbVie Inc. issued a press release announcing financial results for the first quarter ended March 31, 2024.&#160; A copy of the press release is furnished as Exhibit&#160;99.1 to this report and incorporated herein by reference.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Item 9.01  Financial Statements and Exhibits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(d) Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:11.363%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.745%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20240331xexhibit991.htm">99.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20240331xexhibit991.htm">Press Release dated April 2</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20240331xexhibit991.htm">6</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20240331xexhibit991.htm">, 202</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20240331xexhibit991.htm">4</a><a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:none" href="abbv-20240331xexhibit991.htm"> (furnished pursuant to Item 2.02).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).</span></td></tr></table></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.340%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ABBVIE INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">April 26, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">/s/ Scott T. Reents</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Scott T. Reents</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Executive Vice President,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>abbv-20240331xexhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i5df3655150f84467a73e42d808f3a5aa_1"></div><div style="min-height:45pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><img alt="abbvieimage1a53a.jpg" src="abbvieimage1a53a.jpg" style="height:25px;margin-bottom:5pt;vertical-align:text-bottom;width:150px"></div><div><font style="color:#071d49;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="margin-top:24pt"><font style="color:#071d49;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">PRESS RELEASE</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">AbbVie Reports First-Quarter 2024 Financial Results</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;   </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent&#59; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent&#59; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&#38;D and Milestones Expense </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Delivers First-Quarter Net Revenues of $12.310 Billion, an Increase of 0.7 Percent on a Reported Basis and 1.6 Percent on an Operational Basis</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">First-Quarter Global Net Revenues from the Immunology Portfolio Were $5.371 Billion, a Decrease of 3.9 Percent on a Reported Basis, or 3.1 Percent on an Operational Basis, Due to Humira Biosimilar Competition&#59; Global Humira Net Revenues Were $2.270 Billion&#59; Global Skyrizi Net Revenues Were $2.008 Billion&#59; Global Rinvoq Net Revenues Were $1.093 Billion</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">First-Quarter Global Net Revenues from the Oncology Portfolio Were $1.543 Billion, an Increase of 9.0 Percent on a Reported Basis, or 9.8 Percent on an Operational Basis&#59; Global Imbruvica Net Revenues Were $838 Million&#59; Global Venclexta Net Revenues Were $614 Million</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">First-Quarter Global Net Revenues from the Neuroscience Portfolio Were $1.965 Billion, an Increase of 15.9 Percent on a Reported Basis, or 16.0 Percent on an Operational Basis&#59; Global Botox Therapeutic Net Revenues Were $748 Million&#59; Global Vraylar Net Revenues Were $694 Million&#59; Combined Global Ubrelvy and Qulipta Net Revenues Were $334 Million</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">First-Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.249 Billion, a Decrease of 4.0 Percent on a Reported Basis, or 2.5 Percent on an Operational Basis&#59; Global Botox Cosmetic Net Revenues Were $633 Million&#59; Global Juvederm Net Revenues Were $297 Million</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Successfully Completed Acquisition of ImmunoGen and its Flagship Cancer Therapy, Elahere</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Raises 2024 Adjusted Diluted EPS Guidance Range from $10.97 - $11.17 to $11.13 - $11.33, which Includes an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&#38;D and Milestones Expense Incurred During the First Quarter 2024</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NORTH CHICAGO,&#160;Ill.,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> April&#160;26, 2024 &#8211; AbbVie (NYSE&#58;ABBV) announced financial results for the first quarter ended March 31, 2024.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#34;We continue to demonstrate outstanding operational execution and delivered another quarter of strong results,&#34; said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. &#34;I couldn&#8217;t be more proud of the organization we have built over the past 11 years. We&#8217;ve established an exemplary company culture, developed a productive R&#38;D engine, delivered top-tier financial performance and made a remarkable impact on patients and the communities we serve.&#34;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#34;I want to thank Rick for his exceptional leadership since AbbVie&#8217;s inception and I am deeply honored to serve as the company's next CEO,&#34; said Robert A. Michael, president and chief operating officer, AbbVie. &#34;First quarter results were well ahead of our expectations, driven by excellent performance from our ex-Humira growth platform. Based on our strong results and significant momentum, we are raising our full-year outlook.&#34;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:47.956%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.956%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Note&#58; &#34;Operational&#34; comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td></tr></table></div></div></div><div id="i5df3655150f84467a73e42d808f3a5aa_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:118%">First-Quarter Results</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:118%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:12.53pt">Worldwide net revenues were $12.310 billion, an increase of 0.7 percent on a reported basis, or 1.6 percent on an operational basis.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:12.53pt">Global net revenues from the immunology portfolio were $5.371 billion, a decrease of 3.9 percent on a reported basis, or 3.1 percent on an operational basis, due to Humira biosimilar competition.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:14.25pt">Global Humira net revenues of $2.270 billion decreased 35.9 percent on a reported basis, or 35.2 percent on an operational basis. U.S. Humira net revenues were $1.771 billion, a decrease of 39.9 percent. Internationally, Humira net revenues were $499 million, a decrease of 15.8 percent on a reported basis, or 11.6 percent on an operational basis.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:14.25pt">Global Skyrizi net revenues were $2.008 billion, an increase of 47.6 percent on a reported basis, or 48.0 percent on an operational basis.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:14.25pt">Global Rinvoq net revenues were $1.093 billion, an increase of 59.3 percent on a reported basis, or 61.9 percent on an operational basis.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:12.53pt">Global net revenues from the oncology portfolio were $1.543 billion, an increase of 9.0 percent on a reported basis, or 9.8 percent on an operational basis. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:14.25pt">Global Imbruvica net revenues were $838 million, a decrease of 4.5 percent, with U.S. net revenues of $610 million and international profit sharing of $228 million. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:14.25pt">Global Venclexta net revenues were $614 million, an increase of 14.2 percent on a reported basis, or 16.3 percent on an operational basis.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:14.25pt">Global Elahere net revenues were $64&#160;million, reflecting a partial quarter of sales based on the February 12, 2024 close date of the ImmunoGen acquisition.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:12.53pt">Global net revenues from the neuroscience portfolio were $1.965 billion, an increase of 15.9 percent on a reported basis, or 16.0 percent on an operational basis. </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:14.25pt">Global Botox Therapeutic net revenues were $748 million, an increase of 4.1 percent on a reported basis, or 4.5 percent on an operational basis.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:14.25pt">Global Vraylar net revenues were $694 million, an increase of 23.6 percent.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:14.25pt">Global Ubrelvy net revenues were $203 million, an increase of 33.8 percent.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:14.25pt">Global Qulipta net revenues were $131&#160;million, an increase of 97.7 percent.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:12.53pt">Global net revenues from the aesthetics portfolio were $1.249 billion, a decrease of 4.0 percent on a reported basis, or 2.5 percent on an operational basis.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:14.25pt">Global Botox Cosmetic net revenues were $633 million, a decrease of 3.9 percent on a reported basis, or 2.6 percent on an operational basis.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#9702;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:14.25pt">Global Juvederm net revenues were $297 million, a decrease of 16.4 percent on a reported basis, or 13.7 percent on an operational basis.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:12.53pt">On a GAAP basis, the gross margin ratio in the first quarter was 66.7 percent. The adjusted gross margin ratio was 82.9 percent.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:12.53pt">On a GAAP basis, selling, general and administrative (SG&#38;A) expense was 26.9 percent of net revenues. The adjusted SG&#38;A expense was 24.6 percent of net revenues. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:12.53pt">On a GAAP basis, research and development (R&#38;D) expense was 15.8 percent of net revenues. The adjusted R&#38;D expense was 14.7 percent of net revenues. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:12.53pt">Acquired IPR&#38;D and milestones expense was 1.3 percent of net revenues.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:12.53pt">On a GAAP basis, the operating margin in the first quarter was 22.7 percent. The adjusted operating margin was 42.2 percent.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:12.53pt">On a GAAP basis, net interest expense was $453 million. The adjusted net interest expense was $429 million. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:12.53pt">On a GAAP basis, the tax rate in the quarter was 21.8 percent. The adjusted tax rate was 14.8 percent.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:12.53pt">Diluted EPS in the first quarter was $0.77 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $2.31. These results include an unfavorable impact of $0.08 per share related to acquired IPR&#38;D and milestones expense.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:47.956%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.956%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Note&#58; &#34;Operational&#34; comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div></td></tr></table></div></div></div><div id="i5df3655150f84467a73e42d808f3a5aa_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recent Events</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">AbbVie announced that its board of directors unanimously selected Robert A. Michael, AbbVie's current president and chief operating officer, to succeed Richard A. Gonzalez as the company's chief executive officer (CEO). Mr. Gonzalez, who has served as CEO since AbbVie's formation in 2013, will retire from the role of CEO and become executive chairman of the board of directors, effective July 1, 2024. Additionally, the board has appointed Mr. Michael as a member of the board of directors effective July 1, 2024.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">AbbVie announced that it completed its acquisition of ImmunoGen. This transaction added ImmunoGen&#8217;s flagship antibody-drug conjugate (ADC), Elahere (mirvetuximab soravtansine-gynx), for folate receptor-alpha (FR&#945;)-positive platinum-resistant ovarian cancer (PROC), to AbbVie's portfolio. Late-stage development programs for Elahere provide opportunity to expand into additional patient populations. The transaction also included a pipeline of ADCs that further build on AbbVie's existing oncology pipeline of novel targeted therapies and next-generation immuno-oncology assets, which have the potential to create new treatment possibilities across multiple solid tumors and hematologic malignancies.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">AbbVie announced that the U.S. Food and Drug Administration (FDA) granted full approval for Elahere</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">for the treatment of FR&#945;-positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal adult cancer patients treated with up to three prior therapies. The full approval of Elahere was based on the confirmatory MIRASOL Phase 3 trial in which data showed that Elahere treatment resulted in an overall survival (OS) benefit and reduced the risk of cancer progression by 35%.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">AbbVie announced that the FDA granted Priority Review of the supplemental Biologics License Application (sBLA) for Epkinly (epcoritamab), for the treatment of adult relapsed or refractory (R&#47;R) follicular lymphoma (FL) after two or more lines of therapy. If approved, Epkinly will be the only subcutaneous bispecific antibody to treat adults with R&#47;R FL after two lines of prior therapy, marking its second indication following FDA and European Medicines Agency (EMA) approval of R&#47;R third-line diffuse large B-cell lymphoma (DLBCL) treatment. The FDA had previously granted this investigational indication Breakthrough Therapy Designation (BTD). The sBLA is supported by data from the Phase 1&#47;2 EPCORE NHL-1 clinical trial. Epkinly is being co-developed by AbbVie and Genmab.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">AbbVie announced positive top-line results from the Phase 3 SELECT-GCA study, showing Rinvoq (upadacitinib, 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remission from week 12 through week 52 in adults with giant cell arteritis (GCA). In this study, 46 percent of patients receiving Rinvoq in combination with a 26-week steroid taper regimen achieved sustained remission compared to 29 percent of patients receiving placebo in combination with a 52-week steroid taper regimen. Rinvoq&#8217;s safety profile in GCA was generally consistent with that in approved indications, and no new safety signals were identified.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">AbbVie announced positive topline results from the Phase 3b&#47;4 LEVEL UP study, that evaluated the efficacy and safety of Rinvoq (15 mg, once daily starting dose and dose-adjusted based on clinical response) versus Dupixent (dupilumab) in adults and adolescents with moderate to severe atopic dermatitis (AD) who had inadequate response to systemic therapy or when use of those therapies was inadvisable. Rinvoq demonstrated superiority versus Dupixent in the primary endpoint of simultaneous achievement of near complete skin clearance (Eczema Area and Severity Index 90) and no to little itch (Worst Pruritus Numerical Rating Scale of 0 or 1) at Week 16. Rinvoq also showed superiority versus Dupixent for all ranked secondary endpoints, including the rapid onset of achieving near complete skin clearance and no to little itch. The safety profile of Rinvoq was consistent with the profile in previous AD studies with no new safety signals identified during the 16-week period.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Recent Events (Continued)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">At the Congress of European Crohn&#8217;s and Colitis Organisation (ECCO), AbbVie presented 17 abstracts, including nine oral presentations and eight posters, from a range of studies across its inflammatory bowel disease (IBD) portfolio. Oral presentations included new post-hoc analysis of clinical and endoscopic outcomes from the Phase 3 SEQUENCE trial comparing Skyrizi (risankizumab) versus Stelara (ustekinumab) in patients with moderate to severe Crohn&#8217;s disease (CD), results from the Phase 3 COMMAND study of Skyrizi as a maintenance therapy in adult patients with moderately to severely active ulcerative colitis (UC), and long-term safety results from the Phase 3 U-ENDURE trial of Rinvoq in adult patients with moderately to severely active CD. Skyrizi is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">At the 2024 American Academy of Dermatology (AAD) Annual Meeting, AbbVie presented 29 abstracts including three late-breaking presentations. The presented data across AbbVie and Allergan Aesthetics' extensive portfolios reinforce the companies' ongoing commitment to developing transformative medical dermatology and aesthetic treatments to advance and redefine the standard of care for patients.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">Allergan Aesthetics announced the FDA approval of Juvederm Voluma XC for injection in the temple region to improve moderate to severe temple hollowing in adults over the age of 21. Juvederm Voluma XC is the first and only hyaluronic acid (HA) dermal filler to receive FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">At the American Academy of Neurology (AAN) Annual Meeting, AbbVie announced an interim analysis of an ongoing 156-week extension study that supports the long-term safety, tolerability and efficacy of Qulipta (atogepant) to prevent chronic and episodic migraine. The overall long-term safety results were consistent with the known safety profile of Qulipta in chronic and episodic migraine, and no new safety signals were identified. These results also support improvements in key efficacy outcomes, including reduction in monthly acute medication use days</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">AbbVie and Landos Biopharma announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases. Landos' lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of UC.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">AbbVie and OSE Immunotherapeutics, a clinical-stage immunotherapy company, announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">AbbVie and Tentarix Biotherapeutics announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology. The collaboration will leverage AbbVie's therapeutic area expertise and Tentarix's Tentacles platform.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Full-Year 2024 Outlook</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.97 - $11.17 to $11.13 - $11.33, which includes an unfavorable impact of $0.08 per share related to acquired IPR&#38;D and milestones expense incurred during the first quarter 2024. The company's 2024 adjusted diluted EPS guidance excludes any impact from acquired IPR&#38;D and milestones that may be incurred beyond the first quarter of 2024, as both cannot be reliably forecasted.</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About AbbVie</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas&#58; immunology, oncology, neuroscience and eye care - and products and services across our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.abbvie.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Follow </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">&#64;abbvie</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> on X (formerly Twitter), </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Facebook, Instagram</font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">YouTube</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;or </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">LinkedIn</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Conference Call</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">AbbVie will host an investor conference call today at 8&#58;00 a.m. Central Time to discuss our first-quarter performance. The call will be webcast through AbbVie&#8217;s Investor Relations website at </font><font style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">investors.abbvie.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. An archived edition of the call will be available after 11&#58;00 a.m. Central Time.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-GAAP Financial Results</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Financial results for 2024 and 2023 are presented on both a reported and a non-GAAP basis. Reported results were prepared in accordance with GAAP and include all revenue and expenses recognized during the period. Non-GAAP results adjust for certain non-cash items and for factors that are unusual or unpredictable, and exclude those costs, expenses, and other specified items presented in the reconciliation tables later in this release. AbbVie&#8217;s management believes non-GAAP financial measures provide useful information to investors regarding AbbVie&#8217;s results of operations and assist management, analysts, and investors in evaluating the performance of the business. Non-GAAP financial measures should be considered in addition to, and not as a substitute for, measures of financial performance prepared in accordance with GAAP. </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Forward-Looking Statements</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;project&#8221; and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks related to the proposed acquisition of Cerevel Therapeutics, including the possibility that the acquisition may not be consummated on the anticipated timeframe or at all, risks related to the ability to realize the anticipated benefits of the proposed acquisition on the anticipated timeframe or at all, risks that the costs to consummate the proposed acquisition or to obtain the anticipated benefits of the proposed acquisition could be greater than expected, the risk that an event occurs that could give rise to the right of AbbVie, on the one hand, or Cerevel Therapeutics, on the other hand, to terminate the acquisition agreement for such transaction, the risk that the business will not be integrated successfully, disruption from the proposed acquisition making it more difficult to maintain business and operational relationships, the diversion of management&#8217;s attention from ongoing business operations and opportunities, negative effects of the consummation of the proposed acquisition on business or employee relationships or the market price of the Company&#8217;s common stock and&#47;or operating results, significant transaction costs, the assumption of unknown liabilities, the risk of litigation and&#47;or regulatory actions related to the proposed acquisition of Cerevel Therapeutics's business, risks related to the financing of the proposed acquisition, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie&#8217;s and Cerevel Therapeutics's operations is set forth in Item 1A, &#8220;Risk Factors,&#8221; of AbbVie&#8217;s 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information&#59; Item 1A, &#8220;Risk Factors,&#8221; of Cerevel Therapeutics's 2023 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that Cerevel Therapeutics subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.</font></div><div style="margin-top:11pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.724%"><tr><td style="width:1.0%"></td><td style="width:59.997%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Media&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Investors&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Gabby Tarbert</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Liz Shea</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(224) 244-0111</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(847) 935-2211</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Todd Bosse</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(847) 936-1182</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Jeffrey Byrne</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:100%">(847) 938-2923</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="i5df3655150f84467a73e42d808f3a5aa_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Key Product Revenues</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Quarter Ended March 31, 2024</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change vs. 1Q23</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Revenues (in millions)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Reported</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operational</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">a</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">U.S.</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Int&#8217;l.</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">U.S.</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Int&#8217;l.</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Int&#8217;l.</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Total</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET REVENUES</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$9,041</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$3,269</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$12,310</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.7)%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.1%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.7%</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11.6%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.6%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,152</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,219</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,371</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.9)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.1)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Humira</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,771</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,270</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.9)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.2)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skyrizi</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,008</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.6</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.0</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rinvoq</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.3</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.9</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">967</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">576</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,543</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.0</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imbruvica</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">b</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">610</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">838</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Venclexta</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elahere</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">c</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Epkinly</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">d</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aesthetics</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">776</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">473</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,249</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.0)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.5)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Botox Cosmetic</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Juvederm Collection</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.7)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Aesthetics</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,714</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">251</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,965</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15.9</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.0</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Botox Therapeutic</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">611</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">748</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vraylar</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Duodopa</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ubrelvy</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qulipta</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.7</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.7</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Neuroscience</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.5)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.9)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#62;100.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eye Care</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">227</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">311</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">538</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(29.2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(11.7)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10.4)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ozurdex</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.7)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lumigan&#47;Ganfort</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.5)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.9)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alphagan&#47;Combigan</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47.0)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.7)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.7)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restasis</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44.1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.1)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.3)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Eye Care</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Key Products</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">686</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">214</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">900</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.0)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(2.4)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mavyret</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.8)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.1)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Creon</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n&#47;m</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linzess&#47;Constella</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</font></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7</font></td></tr></table></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">a   </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#34;Operational&#34; comparisons are presented at constant currency rates that reflect comparative local currency net revenues at the prior year's foreign exchange rates.</font></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">b   </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reflects profit sharing for Imbruvica international revenues.</font></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">c   </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reflects partial quarter Elahere revenue based on the February 12, 2024 close date of the ImmunoGen acquisition.</font></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">d   </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Epkinly U.S. revenues reflect profit sharing. International revenues reflect product revenues as well as profit sharing from certain international territories.</font></div><div style="margin-top:5pt;padding-left:9pt;text-indent:-9pt"><font style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">n&#47;m &#61; not meaningful</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7</font></div></div></div><div id="i5df3655150f84467a73e42d808f3a5aa_16"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Consolidated Statements of Earnings </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited) </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.092%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.014%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share data)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;First Quarter<br>Ended March 31</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net revenues</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,310&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,225&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,094&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,986&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,315&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,039&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,939&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,292&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired IPR&#38;D and milestones</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating costs and expenses</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,512&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,457&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating earnings</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,798&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,768&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">453&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net foreign exchange loss</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,804&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before income tax expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,755&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,372&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to noncontrolling interest</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings attributable to AbbVie Inc.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to AbbVie Inc.</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted diluted earnings per share</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">a</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted shares outstanding</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,773&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,776&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">a&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Refer to the Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for further details.</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:10pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8</font></div></div></div><div id="i5df3655150f84467a73e42d808f3a5aa_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reconciliation of GAAP Reported to Non-GAAP Adjusted Information</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited) </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.     Specified items impacted results as follows&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarter Ended March 31, 2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share data)</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After-tax</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">a</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As reported (GAAP)</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,755</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,369</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.77</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted for specified items&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,891&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,603&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration costs</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.27&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As adjusted (non-GAAP)</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,838</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,120</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.31</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">a &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents net earnings attributable to AbbVie Inc. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition and integration costs primarily reflect costs related to the ImmunoGen acquisition.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended March 31, 2024 included acquired IPR&#38;D and milestones expense of $164&#160;million on a pre-tax and $138&#160;million on an after-tax basis, representing an unfavorable impact of $0.08 to both diluted EPS and adjusted diluted EPS. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.     The impact of the specified items by line item was as follows&#58;&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:48.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarter Ended March 31, 2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&#38;A</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&#38;D</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As reported (GAAP)</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,094</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,315</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,939</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">453</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">586</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted for specified items&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,891)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration costs</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(660)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As adjusted</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(non-GAAP)</font></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,108</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,032</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,811</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">429</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(76)</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.     The adjusted tax rate for the first quarter of 2024 was 14.8 percent, as detailed below&#58;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarter Ended March 31, 2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in millions)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax earnings</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rate</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As reported (GAAP)</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,755</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">383</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specified items</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,083&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As adjusted</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(non-GAAP)</font></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,838</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">715</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AbbVie Inc.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reconciliation of GAAP Reported to Non-GAAP Adjusted Information</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(Unaudited)</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.     Specified items impacted results as follows&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarter Ended March 31, 2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share data)</font></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td></tr><tr><td colspan="3" style="padding:2px 4.37pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After-tax</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">a</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As reported (GAAP)</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">475</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">239</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted for specified items&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,948&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,646&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.93&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset impairment</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">710&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration costs</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.03&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration </font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,872&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,822&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.02&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As adjusted (non-GAAP)</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,083</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,385</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.46</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:3.9pt;font-weight:400;line-height:120%;position:relative;top:-2.1pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">a &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Represents net earnings attributable to AbbVie Inc. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition and integration costs reflect integration costs related to the Allergan acquisition.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reported GAAP earnings and adjusted non-GAAP earnings for the three months ended March 31, 2023 included acquired IPR&#38;D and milestones expense of $150&#160;million on a pre-tax and after-tax basis, representing an unfavorable impact of $0.08 to both diluted EPS and adjusted diluted EPS. </font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.     The impact of the specified items by line item was as follows&#58;&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarter Ended March 31, 2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&#38;A</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&#38;D</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other operating income</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense, net</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As reported (GAAP)</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,986</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,039</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,292</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10)</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,804</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted for specified items&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,948)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset impairment</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and integration costs</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,872)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As adjusted</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(non-GAAP)</font></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,931</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,984</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,657</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(69)</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.     The adjusted tax rate for the first quarter of 2023 was 13.7 percent, as detailed below&#58;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quarter Ended March 31, 2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in millions)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-tax earnings</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rate</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As reported (GAAP)</font></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">475</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">234</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specified items</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,608&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As adjusted</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(non-GAAP)</font></div></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,083</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">696</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>abbv-20240426.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:027f36f8-6174-473b-960c-e3409d885536,g:5e3f1b59-dc6f-431a-ad79-5b605b3de4ca-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:abbv="http://www.abbvie.com/20240426" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.abbvie.com/20240426">
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abbv-20240426_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abbv-20240426_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="abbv-20240426_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://www.abbvie.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="abbv_Sec2125SeniorNotesDue2029Member" abstract="true" name="Sec2125SeniorNotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abbv_Sec0.750SeniorNotesDue2027Member" abstract="true" name="Sec0.750SeniorNotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abbv_Sec2625SeniorNotesDue2028Member" abstract="true" name="Sec2625SeniorNotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abbv_Sec1.375SeniorNotesDue2024Member" abstract="true" name="Sec1.375SeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abbv_Sec2.125SeniorNotesdue2028Member" abstract="true" name="Sec2.125SeniorNotesdue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abbv_Sec1.250SeniorNotesdue2031Member" abstract="true" name="Sec1.250SeniorNotesdue2031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="abbv_Sec1250SeniorNotesDue2024Member" abstract="true" name="Sec1250SeniorNotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>abbv-20240426_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:027f36f8-6174-473b-960c-e3409d885536,g:5e3f1b59-dc6f-431a-ad79-5b605b3de4ca-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.abbvie.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="abbv-20240426.xsd#DocumentandEntityInformationDocument"/>
  <link:definitionLink xlink:role="http://www.abbvie.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_65db0f1a-7fa6-4d31-bf53-a9991e50692d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntitiesTable_65db0f1a-7fa6-4d31-bf53-a9991e50692d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_702743a7-fa3a-47ef-9b98-b58bf6a05242" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_65db0f1a-7fa6-4d31-bf53-a9991e50692d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_702743a7-fa3a-47ef-9b98-b58bf6a05242" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_702743a7-fa3a-47ef-9b98-b58bf6a05242_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_702743a7-fa3a-47ef-9b98-b58bf6a05242" xlink:to="loc_us-gaap_ClassOfStockDomain_702743a7-fa3a-47ef-9b98-b58bf6a05242_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_702743a7-fa3a-47ef-9b98-b58bf6a05242" xlink:to="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cc47d30a-5939-47e5-b483-449b052a51fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:to="loc_us-gaap_CommonStockMember_cc47d30a-5939-47e5-b483-449b052a51fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.375SeniorNotesDue2024Member_64498bb7-10c0-4e52-94ea-d9c22eb15cb3" xlink:href="abbv-20240426.xsd#abbv_Sec1.375SeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:to="loc_abbv_Sec1.375SeniorNotesDue2024Member_64498bb7-10c0-4e52-94ea-d9c22eb15cb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1250SeniorNotesDue2024Member_f30918e3-eaa9-4ad2-9d85-5a3e2d1b36a0" xlink:href="abbv-20240426.xsd#abbv_Sec1250SeniorNotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:to="loc_abbv_Sec1250SeniorNotesDue2024Member_f30918e3-eaa9-4ad2-9d85-5a3e2d1b36a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec0.750SeniorNotesDue2027Member_6e8ec461-4a10-4cef-9d07-fda8eb70b36f" xlink:href="abbv-20240426.xsd#abbv_Sec0.750SeniorNotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:to="loc_abbv_Sec0.750SeniorNotesDue2027Member_6e8ec461-4a10-4cef-9d07-fda8eb70b36f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2.125SeniorNotesdue2028Member_e401fbb3-3fa2-4dda-b808-bfa4be4765e4" xlink:href="abbv-20240426.xsd#abbv_Sec2.125SeniorNotesdue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:to="loc_abbv_Sec2.125SeniorNotesdue2028Member_e401fbb3-3fa2-4dda-b808-bfa4be4765e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2625SeniorNotesDue2028Member_ad335e30-850e-4495-b51b-6c47952a4f89" xlink:href="abbv-20240426.xsd#abbv_Sec2625SeniorNotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:to="loc_abbv_Sec2625SeniorNotesDue2028Member_ad335e30-850e-4495-b51b-6c47952a4f89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2125SeniorNotesDue2029Member_afa91985-d465-4b88-8b91-90fb141599d0" xlink:href="abbv-20240426.xsd#abbv_Sec2125SeniorNotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:to="loc_abbv_Sec2125SeniorNotesDue2029Member_afa91985-d465-4b88-8b91-90fb141599d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.250SeniorNotesdue2031Member_cfbb248c-6194-45b9-90dc-944470e37c12" xlink:href="abbv-20240426.xsd#abbv_Sec1.250SeniorNotesdue2031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:to="loc_abbv_Sec1.250SeniorNotesdue2031Member_cfbb248c-6194-45b9-90dc-944470e37c12" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_d9276ef7-ffa4-4f12-83f2-cdbbf50f267f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsExchangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_65db0f1a-7fa6-4d31-bf53-a9991e50692d" xlink:to="loc_dei_EntityListingsExchangeAxis_d9276ef7-ffa4-4f12-83f2-cdbbf50f267f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_d9276ef7-ffa4-4f12-83f2-cdbbf50f267f_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityListingsExchangeAxis_d9276ef7-ffa4-4f12-83f2-cdbbf50f267f" xlink:to="loc_dei_ExchangeDomain_d9276ef7-ffa4-4f12-83f2-cdbbf50f267f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_dbaa2a38-cf56-4675-9cef-0b44ce9aff56" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ExchangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityListingsExchangeAxis_d9276ef7-ffa4-4f12-83f2-cdbbf50f267f" xlink:to="loc_dei_ExchangeDomain_dbaa2a38-cf56-4675-9cef-0b44ce9aff56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_121b189e-eff2-4d10-ab8a-4beb031785ce" xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNYS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_dbaa2a38-cf56-4675-9cef-0b44ce9aff56" xlink:to="loc_exch_XNYS_121b189e-eff2-4d10-ab8a-4beb031785ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI_f5ceddd6-3520-4673-9f3f-743e50c7227f" xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XCHI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_ExchangeDomain_dbaa2a38-cf56-4675-9cef-0b44ce9aff56" xlink:to="loc_exch_XCHI_f5ceddd6-3520-4673-9f3f-743e50c7227f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8e6b1026-25c3-4726-be33-8069dae4a7a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_DocumentType_8e6b1026-25c3-4726-be33-8069dae4a7a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1c31320c-8152-4ede-9473-608ec2f0b3e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_DocumentPeriodEndDate_1c31320c-8152-4ede-9473-608ec2f0b3e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7a56dc99-4691-46c6-bcb0-fa4d5bd9034d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityRegistrantName_7a56dc99-4691-46c6-bcb0-fa4d5bd9034d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_361a9603-6adb-4b15-8332-9fe24022184c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityCentralIndexKey_361a9603-6adb-4b15-8332-9fe24022184c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_39a223fd-7a95-4a9e-965f-abc05b762687" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_AmendmentFlag_39a223fd-7a95-4a9e-965f-abc05b762687" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ef2a323c-293d-4b5d-a5af-5fc022ba1763" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ef2a323c-293d-4b5d-a5af-5fc022ba1763" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0fa1290c-e5e1-46e2-b766-f09302176f30" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityFileNumber_0fa1290c-e5e1-46e2-b766-f09302176f30" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5cf00faa-3585-43aa-9a98-2dd07010de19" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityTaxIdentificationNumber_5cf00faa-3585-43aa-9a98-2dd07010de19" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_872f41c8-2018-4b25-912c-7c4c57cbcffb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityAddressAddressLine1_872f41c8-2018-4b25-912c-7c4c57cbcffb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c6904fe2-ffe5-4138-a6ac-3f99226706c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityAddressCityOrTown_c6904fe2-ffe5-4138-a6ac-3f99226706c9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c554015e-556d-4d71-a7a8-2ea8e3833d4e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityAddressStateOrProvince_c554015e-556d-4d71-a7a8-2ea8e3833d4e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f60d40e3-ab58-46cc-a67c-ba18ba7d36a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityAddressPostalZipCode_f60d40e3-ab58-46cc-a67c-ba18ba7d36a1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f252d6db-fb15-4b3b-a685-259e145f47a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_CityAreaCode_f252d6db-fb15-4b3b-a685-259e145f47a1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7d790259-e690-40e7-91d0-d56a555f4dfd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_LocalPhoneNumber_7d790259-e690-40e7-91d0-d56a555f4dfd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_15b2dfc6-dc77-4f0a-ad37-e8ca4e8a4be7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_WrittenCommunications_15b2dfc6-dc77-4f0a-ad37-e8ca4e8a4be7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_61fbf96d-7102-4ccf-9f68-8b883ab3aede" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_SolicitingMaterial_61fbf96d-7102-4ccf-9f68-8b883ab3aede" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_e4ec8beb-11de-494c-b7a7-3737195d9460" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_PreCommencementTenderOffer_e4ec8beb-11de-494c-b7a7-3737195d9460" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_aea57db9-01a5-4885-b16a-b07df40d310c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_aea57db9-01a5-4885-b16a-b07df40d310c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bd9a5bb9-b2b1-4c07-bee6-558bdc821b51" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_Security12bTitle_bd9a5bb9-b2b1-4c07-bee6-558bdc821b51" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8c483b1a-715f-4cbc-8277-4ec9aa30c905" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_TradingSymbol_8c483b1a-715f-4cbc-8277-4ec9aa30c905" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c216fdf6-3508-45c3-a187-11ffddd675a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_SecurityExchangeName_c216fdf6-3508-45c3-a187-11ffddd675a1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ee37f10e-9da8-4a1b-818c-26e13a0583c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityEmergingGrowthCompany_ee37f10e-9da8-4a1b-818c-26e13a0583c9" xlink:type="arc" order="21"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>abbv-20240426_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:027f36f8-6174-473b-960c-e3409d885536,g:5e3f1b59-dc6f-431a-ad79-5b605b3de4ca-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_abbv_Sec2125SeniorNotesDue2029Member_2053814e-1c1e-4d4f-80cd-efff6753fd7b_terseLabel_en-US" xlink:label="lab_abbv_Sec2125SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sec 2.125 Senior Notes Due 2029</link:label>
    <link:label id="lab_abbv_Sec2125SeniorNotesDue2029Member_label_en-US" xlink:label="lab_abbv_Sec2125SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sec 2.125 Senior Notes Due 2029 [Member]</link:label>
    <link:label id="lab_abbv_Sec2125SeniorNotesDue2029Member_documentation_en-US" xlink:label="lab_abbv_Sec2125SeniorNotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sec 2.125 Senior Notes Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2125SeniorNotesDue2029Member" xlink:href="abbv-20240426.xsd#abbv_Sec2125SeniorNotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec2125SeniorNotesDue2029Member" xlink:to="lab_abbv_Sec2125SeniorNotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec1.375SeniorNotesDue2024Member_2ebdd413-9d8f-46b8-94d0-a4698e2db3be_terseLabel_en-US" xlink:label="lab_abbv_Sec1.375SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sec 1.375 Senior Notes Due 2024</link:label>
    <link:label id="lab_abbv_Sec1.375SeniorNotesDue2024Member_label_en-US" xlink:label="lab_abbv_Sec1.375SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sec 1.375 Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_abbv_Sec1.375SeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_abbv_Sec1.375SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sec 1.375 Senior Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.375SeniorNotesDue2024Member" xlink:href="abbv-20240426.xsd#abbv_Sec1.375SeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec1.375SeniorNotesDue2024Member" xlink:to="lab_abbv_Sec1.375SeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ExchangeDomain_8471653d-26f1-4a7a-8fcb-7aca97c0f529_terseLabel_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:label id="lab_dei_ExchangeDomain_label_en-US" xlink:label="lab_dei_ExchangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ExchangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ExchangeDomain" xlink:to="lab_dei_ExchangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_ae02ed40-491d-438a-8d35-7be69317cbe3_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f6fafdb7-1f16-4f17-9735-697faf4ef29e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_8c7b147f-3136-4538-87a2-5b7a53e3356a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_9dd65edb-5fc9-44fd-a5d9-7ea9a32c37b9_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_5c151508-7bbe-43a3-b55e-c60bab6cbfcf_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_77f59e79-04d2-458d-a083-fbf885e3159a_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_e8528d07-9228-4ff5-b23f-baa312175061_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bbb98b7c-f285-47c8-bda5-b56d67c2919b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_4dd03bef-e739-4301-8868-a09aadea07e6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XNYS_24840fda-aef7-4a79-9f6a-52412357a782_terseLabel_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NEW YORK STOCK EXCHANGE, INC.</link:label>
    <link:label id="lab_exch_XNYS_label_en-US" xlink:label="lab_exch_XNYS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NEW YORK STOCK EXCHANGE, INC. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS" xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNYS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XNYS" xlink:to="lab_exch_XNYS" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9b27a0de-54f5-4604-9411-571e011a1a5c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec1250SeniorNotesDue2024Member_fa1d8233-df1b-4fb7-a5cd-362fdf6b8879_terseLabel_en-US" xlink:label="lab_abbv_Sec1250SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sec 1.250 Senior Notes Due 2024</link:label>
    <link:label id="lab_abbv_Sec1250SeniorNotesDue2024Member_label_en-US" xlink:label="lab_abbv_Sec1250SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sec 1.250 Senior Notes Due 2024 [Member]</link:label>
    <link:label id="lab_abbv_Sec1250SeniorNotesDue2024Member_documentation_en-US" xlink:label="lab_abbv_Sec1250SeniorNotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sec 1.250 Senior Notes Due 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1250SeniorNotesDue2024Member" xlink:href="abbv-20240426.xsd#abbv_Sec1250SeniorNotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec1250SeniorNotesDue2024Member" xlink:to="lab_abbv_Sec1250SeniorNotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec0.750SeniorNotesDue2027Member_1e4d3c8a-984f-4581-b528-2820c906c79b_terseLabel_en-US" xlink:label="lab_abbv_Sec0.750SeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sec 0.750 Senior Notes Due 2027</link:label>
    <link:label id="lab_abbv_Sec0.750SeniorNotesDue2027Member_label_en-US" xlink:label="lab_abbv_Sec0.750SeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sec 0.750 Senior Notes Due 2027 [Member]</link:label>
    <link:label id="lab_abbv_Sec0.750SeniorNotesDue2027Member_documentation_en-US" xlink:label="lab_abbv_Sec0.750SeniorNotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sec 0.750 Senior Notes Due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec0.750SeniorNotesDue2027Member" xlink:href="abbv-20240426.xsd#abbv_Sec0.750SeniorNotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec0.750SeniorNotesDue2027Member" xlink:to="lab_abbv_Sec0.750SeniorNotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_051dc9fe-a923-4d7d-877b-942e823355e3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_249d1ff4-dbf3-4c6f-b399-219c8a2c43ed_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_36922ef1-79fc-42d5-9d1b-e1ce1e3e410b_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_b6c0ae09-61e4-4dba-a433-fb8ead69d4e7_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e89c851e-6b09-492d-a60a-3369ef12d69d_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9875367b-fea2-4536-a2d5-9a173d980952_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_11616a9d-17a4-4118-aea7-22b1dd936524_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec1.250SeniorNotesdue2031Member_112d53d7-e3e7-4d58-a9cf-bd2a3463a3a0_terseLabel_en-US" xlink:label="lab_abbv_Sec1.250SeniorNotesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sec 1.250 Senior Notes due 2031</link:label>
    <link:label id="lab_abbv_Sec1.250SeniorNotesdue2031Member_label_en-US" xlink:label="lab_abbv_Sec1.250SeniorNotesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sec 1.250 Senior Notes due 2031 [Member]</link:label>
    <link:label id="lab_abbv_Sec1.250SeniorNotesdue2031Member_documentation_en-US" xlink:label="lab_abbv_Sec1.250SeniorNotesdue2031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sec 1.250 Senior Notes due 2031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.250SeniorNotesdue2031Member" xlink:href="abbv-20240426.xsd#abbv_Sec1.250SeniorNotesdue2031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec1.250SeniorNotesdue2031Member" xlink:to="lab_abbv_Sec1.250SeniorNotesdue2031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_2b0bbdc1-2368-4997-b3ba-43e092549943_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec2.125SeniorNotesdue2028Member_b45edd6e-63fc-427e-9c5a-0a7e99aef830_terseLabel_en-US" xlink:label="lab_abbv_Sec2.125SeniorNotesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sec 2.125 Senior Notes due 2028</link:label>
    <link:label id="lab_abbv_Sec2.125SeniorNotesdue2028Member_label_en-US" xlink:label="lab_abbv_Sec2.125SeniorNotesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sec 2.125 Senior Notes due 2028 [Member]</link:label>
    <link:label id="lab_abbv_Sec2.125SeniorNotesdue2028Member_documentation_en-US" xlink:label="lab_abbv_Sec2.125SeniorNotesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sec 2.125 Senior Notes due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2.125SeniorNotesdue2028Member" xlink:href="abbv-20240426.xsd#abbv_Sec2.125SeniorNotesdue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec2.125SeniorNotesdue2028Member" xlink:to="lab_abbv_Sec2.125SeniorNotesdue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_7d0b860e-f036-41c2-8ffa-0f93c53cadb5_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_3562eaf4-c174-4a1b-8bba-0765bee7c3af_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityListingsExchangeAxis_6f5e3955-f269-492f-83fa-a935e709f14d_terseLabel_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:label id="lab_dei_EntityListingsExchangeAxis_label_en-US" xlink:label="lab_dei_EntityListingsExchangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Listings, Exchange [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsExchangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityListingsExchangeAxis" xlink:to="lab_dei_EntityListingsExchangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b5f5d325-e398-4ac6-a434-1183407c7100_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_63c54145-d949-4377-83ab-3d9c16319d8f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_exch_XCHI_b6b2577f-690c-4a9e-9556-0ee2b99ba523_terseLabel_en-US" xlink:label="lab_exch_XCHI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CHICAGO STOCK EXCHANGE, INC</link:label>
    <link:label id="lab_exch_XCHI_label_en-US" xlink:label="lab_exch_XCHI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NYSE CHICAGO, INC. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI" xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XCHI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exch_XCHI" xlink:to="lab_exch_XCHI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_d800cce8-dbbc-49a8-a9e7-171ae736e13a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_75f9c010-8928-40ad-b75c-3876367a434f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_abbv_Sec2625SeniorNotesDue2028Member_7694cac5-1b2d-4947-930e-1d625ce9ff63_terseLabel_en-US" xlink:label="lab_abbv_Sec2625SeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sec 2.625 Senior Notes Due 2028</link:label>
    <link:label id="lab_abbv_Sec2625SeniorNotesDue2028Member_label_en-US" xlink:label="lab_abbv_Sec2625SeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sec 2.625 Senior Notes Due 2028 [Member]</link:label>
    <link:label id="lab_abbv_Sec2625SeniorNotesDue2028Member_documentation_en-US" xlink:label="lab_abbv_Sec2625SeniorNotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sec 2.625 Senior Notes Due 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2625SeniorNotesDue2028Member" xlink:href="abbv-20240426.xsd#abbv_Sec2625SeniorNotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_abbv_Sec2625SeniorNotesDue2028Member" xlink:to="lab_abbv_Sec2625SeniorNotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_5e8dfaaa-942c-467f-b9bb-594ce0396f69_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_bf6f41ee-6ea9-40ea-91e0-7f053561c838_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_999f8ec9-544a-4791-9752-7bbc8b8d0a76_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f0a19dd2-fb68-40b3-8939-8f8c7723bc09_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>abbv-20240426_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:027f36f8-6174-473b-960c-e3409d885536,g:5e3f1b59-dc6f-431a-ad79-5b605b3de4ca-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.abbvie.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="abbv-20240426.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://www.abbvie.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_89ca61d5-bc8a-4a81-9cb0-f14b755c32ec" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_65db0f1a-7fa6-4d31-bf53-a9991e50692d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_89ca61d5-bc8a-4a81-9cb0-f14b755c32ec" xlink:to="loc_dei_EntitiesTable_65db0f1a-7fa6-4d31-bf53-a9991e50692d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_702743a7-fa3a-47ef-9b98-b58bf6a05242" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_65db0f1a-7fa6-4d31-bf53-a9991e50692d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_702743a7-fa3a-47ef-9b98-b58bf6a05242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_702743a7-fa3a-47ef-9b98-b58bf6a05242" xlink:to="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cc47d30a-5939-47e5-b483-449b052a51fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:to="loc_us-gaap_CommonStockMember_cc47d30a-5939-47e5-b483-449b052a51fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.375SeniorNotesDue2024Member_64498bb7-10c0-4e52-94ea-d9c22eb15cb3" xlink:href="abbv-20240426.xsd#abbv_Sec1.375SeniorNotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:to="loc_abbv_Sec1.375SeniorNotesDue2024Member_64498bb7-10c0-4e52-94ea-d9c22eb15cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1250SeniorNotesDue2024Member_f30918e3-eaa9-4ad2-9d85-5a3e2d1b36a0" xlink:href="abbv-20240426.xsd#abbv_Sec1250SeniorNotesDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:to="loc_abbv_Sec1250SeniorNotesDue2024Member_f30918e3-eaa9-4ad2-9d85-5a3e2d1b36a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec0.750SeniorNotesDue2027Member_6e8ec461-4a10-4cef-9d07-fda8eb70b36f" xlink:href="abbv-20240426.xsd#abbv_Sec0.750SeniorNotesDue2027Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:to="loc_abbv_Sec0.750SeniorNotesDue2027Member_6e8ec461-4a10-4cef-9d07-fda8eb70b36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2.125SeniorNotesdue2028Member_e401fbb3-3fa2-4dda-b808-bfa4be4765e4" xlink:href="abbv-20240426.xsd#abbv_Sec2.125SeniorNotesdue2028Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:to="loc_abbv_Sec2.125SeniorNotesdue2028Member_e401fbb3-3fa2-4dda-b808-bfa4be4765e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2625SeniorNotesDue2028Member_ad335e30-850e-4495-b51b-6c47952a4f89" xlink:href="abbv-20240426.xsd#abbv_Sec2625SeniorNotesDue2028Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:to="loc_abbv_Sec2625SeniorNotesDue2028Member_ad335e30-850e-4495-b51b-6c47952a4f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec2125SeniorNotesDue2029Member_afa91985-d465-4b88-8b91-90fb141599d0" xlink:href="abbv-20240426.xsd#abbv_Sec2125SeniorNotesDue2029Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:to="loc_abbv_Sec2125SeniorNotesDue2029Member_afa91985-d465-4b88-8b91-90fb141599d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_abbv_Sec1.250SeniorNotesdue2031Member_cfbb248c-6194-45b9-90dc-944470e37c12" xlink:href="abbv-20240426.xsd#abbv_Sec1.250SeniorNotesdue2031Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8324895a-2b74-44b4-b615-35ec64f1ef6c" xlink:to="loc_abbv_Sec1.250SeniorNotesdue2031Member_cfbb248c-6194-45b9-90dc-944470e37c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityListingsExchangeAxis_d9276ef7-ffa4-4f12-83f2-cdbbf50f267f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityListingsExchangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_65db0f1a-7fa6-4d31-bf53-a9991e50692d" xlink:to="loc_dei_EntityListingsExchangeAxis_d9276ef7-ffa4-4f12-83f2-cdbbf50f267f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ExchangeDomain_dbaa2a38-cf56-4675-9cef-0b44ce9aff56" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ExchangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityListingsExchangeAxis_d9276ef7-ffa4-4f12-83f2-cdbbf50f267f" xlink:to="loc_dei_ExchangeDomain_dbaa2a38-cf56-4675-9cef-0b44ce9aff56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XNYS_121b189e-eff2-4d10-ab8a-4beb031785ce" xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XNYS"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_dbaa2a38-cf56-4675-9cef-0b44ce9aff56" xlink:to="loc_exch_XNYS_121b189e-eff2-4d10-ab8a-4beb031785ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exch_XCHI_f5ceddd6-3520-4673-9f3f-743e50c7227f" xlink:href="https://xbrl.sec.gov/exch/2023/exch-2023.xsd#exch_XCHI"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_ExchangeDomain_dbaa2a38-cf56-4675-9cef-0b44ce9aff56" xlink:to="loc_exch_XCHI_f5ceddd6-3520-4673-9f3f-743e50c7227f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_65db0f1a-7fa6-4d31-bf53-a9991e50692d" xlink:to="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_8e6b1026-25c3-4726-be33-8069dae4a7a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_DocumentType_8e6b1026-25c3-4726-be33-8069dae4a7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1c31320c-8152-4ede-9473-608ec2f0b3e7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_DocumentPeriodEndDate_1c31320c-8152-4ede-9473-608ec2f0b3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7a56dc99-4691-46c6-bcb0-fa4d5bd9034d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityRegistrantName_7a56dc99-4691-46c6-bcb0-fa4d5bd9034d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_361a9603-6adb-4b15-8332-9fe24022184c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityCentralIndexKey_361a9603-6adb-4b15-8332-9fe24022184c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_39a223fd-7a95-4a9e-965f-abc05b762687" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_AmendmentFlag_39a223fd-7a95-4a9e-965f-abc05b762687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ef2a323c-293d-4b5d-a5af-5fc022ba1763" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ef2a323c-293d-4b5d-a5af-5fc022ba1763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_0fa1290c-e5e1-46e2-b766-f09302176f30" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityFileNumber_0fa1290c-e5e1-46e2-b766-f09302176f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5cf00faa-3585-43aa-9a98-2dd07010de19" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityTaxIdentificationNumber_5cf00faa-3585-43aa-9a98-2dd07010de19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_872f41c8-2018-4b25-912c-7c4c57cbcffb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityAddressAddressLine1_872f41c8-2018-4b25-912c-7c4c57cbcffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c6904fe2-ffe5-4138-a6ac-3f99226706c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityAddressCityOrTown_c6904fe2-ffe5-4138-a6ac-3f99226706c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c554015e-556d-4d71-a7a8-2ea8e3833d4e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityAddressStateOrProvince_c554015e-556d-4d71-a7a8-2ea8e3833d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f60d40e3-ab58-46cc-a67c-ba18ba7d36a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityAddressPostalZipCode_f60d40e3-ab58-46cc-a67c-ba18ba7d36a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f252d6db-fb15-4b3b-a685-259e145f47a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_CityAreaCode_f252d6db-fb15-4b3b-a685-259e145f47a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_7d790259-e690-40e7-91d0-d56a555f4dfd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_LocalPhoneNumber_7d790259-e690-40e7-91d0-d56a555f4dfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_15b2dfc6-dc77-4f0a-ad37-e8ca4e8a4be7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_WrittenCommunications_15b2dfc6-dc77-4f0a-ad37-e8ca4e8a4be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_61fbf96d-7102-4ccf-9f68-8b883ab3aede" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_SolicitingMaterial_61fbf96d-7102-4ccf-9f68-8b883ab3aede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_e4ec8beb-11de-494c-b7a7-3737195d9460" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_PreCommencementTenderOffer_e4ec8beb-11de-494c-b7a7-3737195d9460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_aea57db9-01a5-4885-b16a-b07df40d310c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_aea57db9-01a5-4885-b16a-b07df40d310c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bd9a5bb9-b2b1-4c07-bee6-558bdc821b51" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_Security12bTitle_bd9a5bb9-b2b1-4c07-bee6-558bdc821b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_8c483b1a-715f-4cbc-8277-4ec9aa30c905" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_TradingSymbol_8c483b1a-715f-4cbc-8277-4ec9aa30c905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c216fdf6-3508-45c3-a187-11ffddd675a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_SecurityExchangeName_c216fdf6-3508-45c3-a187-11ffddd675a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ee37f10e-9da8-4a1b-818c-26e13a0583c9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_65733ec3-9179-4a00-ac3d-49f7f4768041" xlink:to="loc_dei_EntityEmergingGrowthCompany_ee37f10e-9da8-4a1b-818c-26e13a0583c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>abbvieimage1a53a.jpg
<TEXT>
begin 644 abbvieimage1a53a.jpg
M_]C_X  02D9)1@ ! 0$!&0$9  #__@ R35),3%]'4D%02$E#4SI;04)"5DE%
M74%"0E9)15]53D-/051?4$U37TQ/1T\N15!3_]L 0P ! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ . %$ P$B  (1
M 0,1 ?_$ !\   (" P # 0$            *"0L"!P@!!08$ __$ $T0   &
M 0," P((!PH/ 0    $" P0%!@< " D1$@H3(10Q%1HB05%88=<6,G%R@9&8
M%Q@C)S-)E[&RLSE"4E598G:)E*&WR-'3\(?_Q  < 0 " P$! 0$
M   &!P,$!0((  '_Q  _$0 " @(! P($! ,#"0D    ! @,$!1$& !(A$S$'
M(D%1%",R815Q@4)RH187,U1C@I&4\$-%559B9972U/_:  P# 0 "$0,1 #\
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MMIA'(M): LE<P[B^4B91@N & J[9VV3,)%"*(KI"HW<)JH*JIFM L/6Y[?\
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MK.%RM>% 2\LV.MQ1J -DM(\*JH \[) UU)#F<18<1P93'32,0%CBNUI'8DZ
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M_?2]^M6E'A6SD_DVK;S-PS<[PHD]D1!W!Y:FE4FRH>9[2N+-=9$0)Y+=8!,
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M6,LNS3@Y%;0UM"Y6\12\@OQ5LC>QK,J];7,RVF&4W#O$'$!2.(?Y!OL^8?>
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M#V\[RC/T$MS5<<,A9L9 Q-HR".U(L,8'L9&+N%+;"+WN5;04KE83\(_O-N<
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MV5)&P3U#)X@Z&?P_+OO?;ODBD5DK#0IEH4A^\%F$U@;&R[ _=VE[3JDZE.0
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M._53?_M X)^]?1\7>YG?JIO_ -H'!/WKZM* ,F/N,0?R"4?ZM>?D?ZO_ "T
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M40B*BCHT-3_A-RHGW&CX%R<R:9S1K%Y#=@XG0FNX3$86K86(D,F/2/W^YKM
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MA],"A(\JRL =E>UCOJ,*F;T>938\5SCB)RSO<PFTJZ!&BF/\CUB^RD-66H)
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M7&QDN0MM<Q/N(JTA6UEF,;G_ &FO;O;*U)Q)CD.FY;V[%)"V>,AGWR3&A[W
M5Y8JP&1>PY52_*-&I>$<OS%22+!.U>[C)>Y5K7H3.(%8@LD+"1"(VV?RG,D0
M))5%)),?*^-8RRK98+-5OHT8-BI*(6DV0H:4=C!G ]G 5C_:+#QU]9#<X'-K
MC,48IQN>S415NP"/3:9&PI09^1!!JX$AEUE;CB125=OR+I';N)-VNX>',55!
MPN=0#@'T'Q@[FP^LU8/V;\*?=%HT:>$6#X_,BR/Q[!%G\L?X54\G:CZQD_\
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92?U7,$?=)(B-(YTFV=M#N8[.SKR3OK__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139804488849424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Apr. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 26,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABBVIE INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001551152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">32-0375147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1 North Waukegan Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">North Chicago<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60064-6400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">932-7900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 Par Value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | CHICAGO STOCK EXCHANGE, INC</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.01 Par Value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">CHX<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1.375SeniorNotesDue2024Member', window );">Sec 1.375 Senior Notes Due 2024 | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.375% Senior Notes due 2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1250SeniorNotesDue2024Member', window );">Sec 1.250 Senior Notes Due 2024 | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.250% Senior Notes due 2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV24B<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abbv_Sec0.750SeniorNotesDue2027Member', window );">Sec 0.750 Senior Notes Due 2027 | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.750% Senior Notes due 2027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2.125SeniorNotesdue2028Member', window );">Sec 2.125 Senior Notes due 2028 | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Senior Notes due 2028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2625SeniorNotesDue2028Member', window );">Sec 2.625 Senior Notes Due 2028 | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.625% Senior Notes due 2028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV28B<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2125SeniorNotesDue2029Member', window );">Sec 2.125 Senior Notes Due 2029 | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">2.125% Senior Notes due 2029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1.250SeniorNotesdue2031Member', window );">Sec 1.250 Senior Notes due 2031 | NEW YORK STOCK EXCHANGE, INC.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.250% Senior Notes due 2031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABBV31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XNYS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XNYS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsExchangeAxis=exch_XCHI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsExchangeAxis=exch_XCHI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1.375SeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec1.375SeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1250SeniorNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec1250SeniorNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec0.750SeniorNotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec0.750SeniorNotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2.125SeniorNotesdue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec2.125SeniorNotesdue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2625SeniorNotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec2625SeniorNotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec2125SeniorNotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec2125SeniorNotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abbv_Sec1.250SeniorNotesdue2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abbv_Sec1.250SeniorNotesdue2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MP %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @ 9SV:6)>*NQS     $P(
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MB^$_7G\!4$L! A0#%     @ 9SV:6 =!36*!    L0   !
M ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !G/9I8J<Y2)>X
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M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( &<]FEB7BKL<P    !,"   +
M      "  =41  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( &<]FE@<.&7J/P$
M #P"   /              "  ;X2  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " !G/9I8)!Z;HJT   #X 0  &@              @ $J%   >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !G/9I899!YDAD!  #/
M P  $P              @ $/%0  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    "0 ) #X"  !9%@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>10</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>10</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="abbv-20240426.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abbvie.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="abbv-20240426.htm">abbv-20240426.htm</File>
    <File>abbv-20240426.xsd</File>
    <File>abbv-20240426_def.xml</File>
    <File>abbv-20240426_lab.xml</File>
    <File>abbv-20240426_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="46">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "abbv-20240426.htm": {
   "nsprefix": "abbv",
   "nsuri": "http://www.abbvie.com/20240426",
   "dts": {
    "inline": {
     "local": [
      "abbv-20240426.htm"
     ]
    },
    "schema": {
     "local": [
      "abbv-20240426.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "abbv-20240426_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "abbv-20240426_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abbv-20240426_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 2,
   "axisCustom": 0,
   "memberStandard": 3,
   "memberCustom": 7,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 10,
   "entityCount": 1,
   "segmentCount": 10,
   "elementCount": 39,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 46
   },
   "report": {
    "R1": {
     "role": "http://www.abbvie.com/role/DocumentandEntityInformationDocument",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "shortName": "Document and Entity Information Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abbv-20240426.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "abbv-20240426.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitiesTable",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entities [Table]",
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInformationLineItems",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Entity Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityListingsExchangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityListingsExchangeAxis",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Listings, Exchange [Axis]",
        "label": "Entity Listings, Exchange [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_ExchangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ExchangeDomain",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange [Domain]",
        "label": "Exchange [Domain]",
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "abbv_Sec0.750SeniorNotesDue2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abbvie.com/20240426",
     "localname": "Sec0.750SeniorNotesDue2027Member",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sec 0.750 Senior Notes Due 2027",
        "label": "Sec 0.750 Senior Notes Due 2027 [Member]",
        "documentation": "Sec 0.750 Senior Notes Due 2027 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "abbv_Sec1.250SeniorNotesdue2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abbvie.com/20240426",
     "localname": "Sec1.250SeniorNotesdue2031Member",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sec 1.250 Senior Notes due 2031",
        "label": "Sec 1.250 Senior Notes due 2031 [Member]",
        "documentation": "Sec 1.250 Senior Notes due 2031 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "abbv_Sec1.375SeniorNotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abbvie.com/20240426",
     "localname": "Sec1.375SeniorNotesDue2024Member",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sec 1.375 Senior Notes Due 2024",
        "label": "Sec 1.375 Senior Notes Due 2024 [Member]",
        "documentation": "Sec 1.375 Senior Notes Due 2024 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "abbv_Sec1250SeniorNotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abbvie.com/20240426",
     "localname": "Sec1250SeniorNotesDue2024Member",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sec 1.250 Senior Notes Due 2024",
        "label": "Sec 1.250 Senior Notes Due 2024 [Member]",
        "documentation": "Sec 1.250 Senior Notes Due 2024"
       }
      }
     },
     "auth_ref": []
    },
    "abbv_Sec2.125SeniorNotesdue2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abbvie.com/20240426",
     "localname": "Sec2.125SeniorNotesdue2028Member",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sec 2.125 Senior Notes due 2028",
        "label": "Sec 2.125 Senior Notes due 2028 [Member]",
        "documentation": "Sec 2.125 Senior Notes due 2028 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "abbv_Sec2125SeniorNotesDue2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abbvie.com/20240426",
     "localname": "Sec2125SeniorNotesDue2029Member",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sec 2.125 Senior Notes Due 2029",
        "label": "Sec 2.125 Senior Notes Due 2029 [Member]",
        "documentation": "Sec 2.125 Senior Notes Due 2029"
       }
      }
     },
     "auth_ref": []
    },
    "abbv_Sec2625SeniorNotesDue2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abbvie.com/20240426",
     "localname": "Sec2625SeniorNotesDue2028Member",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sec 2.625 Senior Notes Due 2028",
        "label": "Sec 2.625 Senior Notes Due 2028 [Member]",
        "documentation": "Sec 2.625 Senior Notes Due 2028"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "exch_XCHI": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/exch/2023",
     "localname": "XCHI",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CHICAGO STOCK EXCHANGE, INC",
        "label": "NYSE CHICAGO, INC. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "exch_XNYS": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/exch/2023",
     "localname": "XNYS",
     "presentation": [
      "http://www.abbvie.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NEW YORK STOCK EXCHANGE, INC.",
        "label": "NEW YORK STOCK EXCHANGE, INC. [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001551152-24-000016-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001551152-24-000016-xbrl.zip
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M]T#SB??09'!4ARY"HFLGGH1[[54:>9&$>^]2:>05.8 QNYY&?H@:,(W\ #6
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M)S>7'R\OOK8_7)P#")$%#(,*"8]3M#&?1/!1PX3U7'O<(FJ/S*<M-)^Q]0D
M.T759+)IV&*L'[*H0;0^0$*_PZK4]]""-19LW-K4GK/^J)E-;X5?%2MMZEK,
M8V8=6!&H?39@VZ=SFRLMMGFVJ*J1F.;9WWL:4Y I&3&U6925#73#_ GL/R G
M .8ISDW@;"4 [JY5]206 GI3]FT*$\^",PL>'N?EV1-M], FP"0RZ=C+V45/
MNV<7BH @\4(#8T)![[#&4H>E!O'\T981557.DD6JP?3"#;%O<)?83:1Z2@BQ
M&X# 0?*88R,69Q+($467+*#$4E"/J(S,Y7,I+W8H+^X5%V.F&+KDX^4?EQ_)
MMR\Q"S'BH* 5(T,XSAC! O(P^41\01.H,H54V9(CL!3V80*E6]A6R:J[X(=V
MDI).S.Q$$<$N%T!]])3@;4%@0;R+%O8/5@MFP4].A#902C#P4D'/H8')F(O1
M]=RS*,MTLV&4. R4@/&^ ",$"XB-D N.\W>G(BJ)A&]8]*^(1USX#MC+2]CF
M'-X3I@<:1W<SD %1(!I$$:Y53 '9#9>ZM0-,3L1,FA[]BF(#/1EN)FX"*=+$
MF=+3QOB!L*N$#(JM/Y>*:4(8V"+!=Q0H#OP;FV!Y<FG^3<%0.0>S@N'K!E&"
M7[\"_OE!1IW3F-=#M+G"$.5'",[,R9\>IJN_^!$\#E_]%,WA13RF:QXZOH&?
M^>0L5D5]BNFK/YDP[R>PL_".\(CN QW-6O2#8-/?\5%FUZ61 "*)1XGBD=6(
M=*2>@'(3F.$$?WDO.C)!%<;4N@Q=D3:>Z[;PI&EI&]MYY/P=XR!&#OA<M@A=
M24]BK89PJT+Q,"QER-6'Q\K6]W=[+"AX>!,[2XH6FW&M9Z4.FYO(9 &#M40F
M.;GP^.1MZ[19UDDU@R<\4@)GPJ)5+-H6^^07OC=;)5-0.E]X#M/0G]ED\4#X
MO)<7%Y]/X^1FJ@)#'1!@Y1!C'6L:PF4) )\-6V'/<KN6?8%M&$TD(&1XB9E$
M!FJ>*>6CU;G\%G%[FU5131QC+F* 8U!F#K'L@#49G5R]!4LBE4_YO/W1)+V!
MJ@"_VYYY&!(QG"5>6X@!O=@"8OMSP4XRF<7B12'F-C/=O-^_77ZZN!0A2%&C
M@EI93!P[\0%Y[G?[;VXT"85[$X*L] UP @'Z[QB1%195XJ#DV5#K)Y6 ?_'N
MM)7OC%Y\_NVW\T]<)S)K,=X=3YH:F$UUF6*.;:S8N,O9D+-<;0E^-GA*-7),
M*LIK3$$^)]\PYX7H=(#NVB'VC@DMG+O;;^W+3^^^7<<X75D 3]K4Q3LE 1<V
MA$-)F*%"6%':V!,9A3$-0>N[Y*U'9WB X.5=P9\.\-6<[9_3O!@W)!@ )[4S
MRSJ5L6/9?6\.1AH.NX]G\D]9_YRS;)B;5F5!R.^/X<:T2\Y-<#[FC#G>,?^$
M)Q]/SM%#.7?=""CQ-TI#UB.U)?^TT4K^K1G(F/G '#*W 5B\(2V3N,F[6H<%
M#87$2X7YSAV'HAQ.W9KU"X%3I6 -WZ;FL&!< X2DYW-.%F4B($5_ 0M]ZO%@
MXGQN\X@UNPZ#$2[;*V:#1>T'K#G'*"W ;*60P?R\> >K6&O JE2MV\2R]ZE%
M)RCY6=@=K]@0=1@FUNVACQ$SL&2'"K##-G&M95AX&#T=GD^Z@/_P,!9 _G/!
M#M5V_TO-N'"()4?P&A'*HF68Q?.PWAEC7%EZ33P[2_(&J_!"<H.)P2T#356R
MMF 'J>IN)$.6"9DM#0>L'!>3'R9XJB?_.C_E1.W HP@Z;H*' S<@C7,\8M>Q
MGU]D\TQ)Q K.,7AI!,^&JCJLX(8SH;R\16C/6? _SEP<?S!_#_>(/?[6,"'U
MLP0^NVTS%O>?<L7]BBG8Y! ,?L_7S$=,) LQJ_9$%$%(::!_;GRQB)Y(%'&"
MW32,L$0(R-)@E2M<Z"8Q/_A(/.+D!*3RE()X#T^1K!:L>CDDYDP0.[ZVL //
MPG(6>^ICD)RKFSC9G6N1L=!R5JCEN^O=N1D1FGA/&..Y[_N/B6=O=%#P"!;'
M6YHC4=V2[W29PI$PUM-^",O>QZ*)L1\S$*,P5G3L=Q$;.[<,RJ79!TNL&;M(
M35@!3;BRN#X:Z/UAF<!B9H"R2#,_8=8-#^P;X$MSS1 !'GU1@"(68FEYT;XC
M5L3)&(F7R<O]QO$W3#:(+?8BW24H(#-*E<"DO8RXJ*[%O>MP-<@M6#.P1!XK
M"CU65D=CCS%0Q(9^84[,5B:<%=VA2OWTGS96 !M<KP*UM$W09X'X[J>/U_]1
M 0D>UF8A;W$?3LNNC_AV(:F\4E3^^>92U-*F"2A-HZ(DU4X]E-P*UUIC"IY9
MP>))=+%=<8'9RL? C[4UO8.K@P3V3(<36ER18K':"IZT!:'O.:R"?*5,A*F5
MQ(#8F!E17.\L5TD;VD[X*\TP# Y)?I4BOZ_H!_OV#Q2S:Q(L35>L8)??Q[8>
ML=F4CG9@HF6SW!I@@8ZGYZ[Z"=H\,M022R?%46-1$X9U?99ML?XQVUU5-+/B
MZN0>$VY+K6^)"7P'"169)BF.3L&&G6L&:]CT0SM81P,\R7XT<49N<K&=S,'<
M8S5U90YFJRKB/=Y?^+_(+RS"]9E?8IA[@J+[-O06[ -[/D A#<#0B*]@9 TA
M&8W79!K?ZIQ<@XO%P\L$T$=>\VRGKGG>74\V?H9?\YS*,*\WH/.&IZ]K75T,
MH/NQP-O0V?Z7\:9Y#N7!O3$?=&XLL60TV=^8+CUQQ^KZ_C#B MMI8;( I,<,
MQ2/8 OBRCW7C8V?)NF-- S>;+Z_V16C9+9;G8_ +A4A^0CI\O_P %!#7LMDL
MNAHKM_2-Q'!TX *DHK5V<K;<>L(M8#'$C!H.'!LLB,W-H0<NKBC9L5@B$(\\
M#O>:,P.O7YV*JF-O[OF^=X>W!:.!QTN9> ].WH6]U%LX" #N,<G>,>,-ED='
M?5,;!KSI>Z596XG*;:W/&V<QA27E8>0V^ZNX@UA<\4K]6]M<?15O<\V*;J;2
MA._C2FL6-A=]CT:*5K!G@J78;K%#C42L._P!8VHR*3^HQ?2.14UA:KQF[B8^
M]>+-W=V=8HS'MS950(+L/^#VX@WB$4.?%4/,JY?][AG'S"&P@NSP'W*"= 4[
M6I*OX(N#0#UM50Q-[UD!K/>]1:YPB +V&^Y_@R_>5 TM_^M%7Z/Q02B'#ZH&
MT50MC'RTL2KPRCV(B*F$TLZV+2X\=T)]IJ)@/>? )@0GGDK8,=PAGGDL(2=B
MC)[/>OD$ODQ,1 B3)"1#9@IT.L10Y@JY /\*C8:O]IS&1E DU#J/1L8F:NJN
M>&%)X[)Q5]0=':-MFG0V\+TE-317\;:NJ6B/QC= V=/JJ?H8A<'!%?XYF$F^
M.;.Q8X%:2>]^N(E\X]:P'68C\I8R5<T]XRJS^"?/;;/18.]MUA:.Y=?W7BK=
M%&[G(8<$*4E1ER>\<K3+X0=]8V035EQYK,,FF03.7!+BQH@6,]BNXU^O)2=A
M(=[A@U4")G *]XE9LH.]S0<AB*%K;'@)F^W$70CNFK,F(&_J IQKWKFH^R;)
MD2<I2.:/,]!,ZF/7$=LMR)89'P#'5F=S(PP^;80Y8PAXY$8!II3A=Y$+FP=G
MBTU.:HD-\8WR3@83Q"5.1A&[Y(^P^.CFP+D4/D7X&R&"@P"OG#$D^T; "I!\
M_@@&6BAS:)1-.0CBTYCR7-88/$R*[EMR&I/DA.?P<N1CA%),H8@".HF<-0<*
M2SUB287E'X;/LK ;'XSQZDU6@]Y%,TF J>?4CEHBSQX*=*Q6!ZA$?TSJ_&)E
MD R"B7"R1Q"D#C4#H&#F10X&0GCN&X2N(# Q2P/ BA/8(:^<#*)Q$-HAII'A
MDZW54O#=U0?2&WJ(<!\YQ%/6ZA>3DCT9)]X6VIY_!XS9_@BN'ZM8#D%,S.^=
M0':P6#';\ V.EPJ2728"S:5WB51#:<MNDQ#AS14GLYY]!K C $XMQ5+FD0^T
MGK3;XQB!6RSSNJ$FMEYA+?I'.TZ1@UY"GB;G/%2LCD8];GG> 4L'A"7=.F="
MCK;87]6S^)]1M)OAYK]B)M2T%_#)S=^ I,7*NOA?6:A+W%X/2XG1$UQR1@*
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M30FZTLCA,:]>]K4S^+'014>U@QY.7=Y.OS>:J(5ALT4R-;-LWD6>Y2UJ=(]
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M,BHPKB.O"5%3U/N:$,N=6]E3-N>L/&ZKPWO[)0FGE^T_2X5A6&@VRC5=^#2
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M*W(8\N.Z=G'X,>IM*C'W*,Q]%:;.#N7(H6ZL/=1 X2I>VG>T=_)U!Y6]_?)
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M%!MG5?GC6556[83>M'WFT7L4Q5.?O*]X-!KY>-H*PH   732XAD)DQ^IYY%
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M##SMP[3 L-6&;3XY+<A=E6KI&ZK)5FW3+B%1EI%G K5NMI1.>(S1A$]Y3E>
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ME[:_G+#54-8N(NKY%I2*CES//8^1*$K^?(;Z]'34VJBT=4 4BP?H=SS^3NZ
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MLO5<?@"FHN)2TFP_\/1AOC]Y-U9_U@^8R2S](,?"0"WJ!LS7G=7NKW0;>=R
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M!IP./I@<4(?&LB2X+YWW3&+@*)]2$!JGL^LAH1 ,EPD,>Z&WG3U+OSJV7&\
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M5%>.N"]>I\@[QYTP)"2%D5MH16RN[ZF76.=;E_#R_SW4>WJ7/XGI=WAP1):
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MW?$-BO[\\MGB<OXG_XFZE\_^"U!+ P04    " !G/9I8_5^+:XH0  !]E0
M%0   &%B8G8M,C R-# T,C9?;&%B+GAM;,5=;7/;-M;]GE_!]?-E=R:P"8(@
MB$R3G:R;MIZF3B9VI^UF=C1XM36510]%)\Z_?T!*LB7Q#0 IYDLB2^ ].%<\
MN!<OO/KAWX]WB^"+RE?S;/GZ!)Z&)X%:BDS.ES>O3WZ__@FD)_]^\^+%#_\
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M!\]AK=LA;N/::([Q']@&.<AYA+,BW#?$=1N9=(RSXG,XR-E=Y+$/J\1#;C+
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M.6XZ',,O7H_@6[ =]"Q^E_W)'\JW(-OT=+[-90-/751V/^0?\^S+W-"909C
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M&#69LC*"@2H$1(<8X02*%*5NF7(+TC1ILP$/]M$]D^@V?]EFU"-XP2N]=G>
M1[+=0VY YMUF>>(TO(=@/2?ONV#@HW.;_][/EPK.**4Z58("',<,Q(1"0 F.
MRE\C$RE/9<B(8UW\!I1IY/KTT-CF15!B!Q^6OL_,[?G)5JH#V7O)U)VX_\-R
M3<2&/RFW9_7[/";71*SU&;G&QKZR_*1NYN6)M651U7[3(8-4R@AH7CXN$G($
M4HHH2'4J"(D0%Z%;KGD ,(T8GS$=Z^$U^L16??Y,O81G2])#;LU,!BCMP.#$
M(FNF4]=72[LV:>UZW(CQ[S<OMN^8?SA;J3<O_A]02P,$%     @ 9SV:6'3U
MAH7^"0  JE,  !4   !A8F)V+3(P,C0P-#(V7W!R92YX;6S5G%M3W,H1Q]_]
M*3;D-0-SU<RXCIURL$]"A6.[#*?.25ZVYM(#*N]*E"0,?/OT+*QM+L8*$J7=
M%U@DH>[^]V]G>EJS^\O?+Y>+V1=HVK*N7NVP7;HS@RK4L:Q.7NW\?OPK,3M_
M?_WBQ2]_(>3/?WPZG+VMP_D2JFZVWX#K(,XNRNYTUIW"[(^Z^5Q^<;./"]>E
MNED2\GKU;_OUV553GIQV,TZY7%^V/MN\I%PG421#"J8ED5IX8@L:" A);31&
M*5'\[>2E I&85Y;$4"0B!7/$16V)\@557D20X?JFB[+Z_#+_\*Z%&897M:L_
M7^V<=MW9R[V]BXN+W4O?+';KYF2/4RKVUE?OW%Q^>>_Z"[&ZFEEK]U9GOU[:
ME@]=B+=E>W_^=G@43F'I2%FUG:M"-M"6+]O5P<,ZN&ZE^D_]FOWPBOP765]&
M\B'".!%L][*-.Z]?S&;7<C3U CY!FN7?OW\ZN&72>?^EA-U0+_?RZ;UUAET5
MWU5=V5T=5#F=*U_7YS".U7V[JS-XM=.6R[,%K(^=-I!>[>2[DIQP*GF1O?EK
MK_ON??/YK($V7Y[/'^*!F]MG'T?V'RX[J")<"[8VOZC#K8L6.5UUL_[/A?.P
M6!V=1RCG^S6^A][XMFM<Z.;&!E>PJ(@/QA'I#",V>$H2DUXK%02'<%NN'$^+
M :VRVT+8/:F_[.&-,<M<Y!=92['2\9ZY:]&>YO=*H1+:8^<7,"]4]#3A.TLG
M5Q 9!2,^*4$<8L] T<+R.,CO6^9N^_U]NM\T858W$1H<D=;V7!/NI?[V>^'F
MBKTSU^"-2#@M%U^]34V]'"-;73V&=M>907]W9AAV@J:!>'B=F!]&MPJMPX$:
M5E<^->GG+3EQ[FQ^A$I#?BOL+US;?DA'71T^O[DLV[G& 5D*ITER N70D(CU
MUA"OC$^%HXI+_@@$R;5^Y?6-I6L28-&UZR/?D/BI,],A,B"Y]7,HO0'(?.__
MVWKIRFIN!)?&*D>XSW.W])+X@BDB%(1")@:I>&R@>PHK][V8!I*1TUN/JO4F
MT%(OEW6U"N W6'IHYB%('05U1%EALQXXXDHC,!3K40RG6')CPW+7B6E9&9K5
MNY ,DGA"1G+)-C^"P':%5D=0E77SONZ@?7L.N62\":9 KXWWFC :*)&@.+$2
M'(DV< Z>J>#%SXK.7I9Z0<$W'(KQ-=T$0+BB/XPE"6J9 4' .83=18PE&D64
M$\ C\P+'V-Y\/&*H%QYB6_ 82]$-H(/NZ@>"T6O4P4"0!<,X&*(>\O0;*<[&
MT1GPFF(TJ2\>CUKJQ8?<$C[&TW0# .&[B/MWP<15,.8F&)"4)>\%$<EQ+.JC
M(]Y0K,^2DQZD+A3(OH \:JD7(&I+ !E/TTT I.#WY\IU+"X*%$108A2%7$)A
M,:68)P4661:+*9F,[<W'(X9ZX5%L"QYC*;H)=+ '8K'K6)*SS.+D&&6AB/3&
M$.,M(Y8FSR13%@?&WG0\8J@7'7I;Z!A+T0V@@^W>+J56 Z%@ZY48CH*H4R %
MLZB2\A;CB &K;2DU!:&Q$NN_>'G$4B\^S);P,9ZF$P+RM7UX=5BV75F=M.\N
MPZFK3F#5%HJ6ZP(2%DTX)Q(4A!,C$B<A>I\43;S0=^K2IS39'[0]S4)WG';J
MB*I.S<:-WS?OE^B=XTX8$I)",0JMB,V%-?42"VSK$AX>QL,M>Q.WU$?(7CV*
ME!-" .CU_,_W_SF:,\X\,Q8(I)3+95Q4.9\?0GGP..YIHP+TR'V^X4T[%%]]
MR_Y70Q,F?4"&ZB%R39[?_7\=S!,Z%&,L</+C-(<KB$TB$2T%#G-!<]YKK'\\
MOVAHPH%]K/S^OW)-/8C?W5IP6%9PT,&RQ=E-"P$!?6<Z=]$H4AI$)-(FG7 )
M;*AD(TSP#]F>IE4Y]@0_6-6)V5CO,CG&:^<&"L\H+PA7Z+S4^,J#$,2@"-&!
M=-H-H^%[:U-/[L,S5X\@XX:D_R,T91W?5?&MZV#.@F""TT ,4SAW001<M^
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M:&EB:70Y.3$N:'1M4$L! A0#%     @ 9SV:6("AU#4O$0  [JH  !$
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M<   86)B=BTR,#(T,#0R-E]P<F4N>&UL4$L%!@     &  8 D0$  ,YZ
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>abbv-20240426_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:abbv="http://www.abbvie.com/20240426"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:exch="http://xbrl.sec.gov/exch/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abbv-20240426.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
        </entity>
        <period>
            <startDate>2024-04-26</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-26</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XCHI</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-26</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.375SeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-26</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1250SeniorNotesDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-26</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec0.750SeniorNotesDue2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-26</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2.125SeniorNotesdue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-26</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2625SeniorNotesDue2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-26</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec2125SeniorNotesDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-26</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001551152</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.250SeniorNotesdue2031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:EntityListingsExchangeAxis">exch:XNYS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-26</startDate>
            <endDate>2024-04-26</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-45">0001551152</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-46">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-04-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">ABBVIE INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-35565</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">32-0375147</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1 North Waukegan Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">North Chicago</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">60064-6400</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">847</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">932-7900</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-2" id="f-17">Common Stock, $0.01 Par Value</dei:Security12bTitle>
    <dei:Security12bTitle contextRef="c-3" id="f-18">Common Stock, $0.01 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-19">ABBV</dei:TradingSymbol>
    <dei:TradingSymbol contextRef="c-2" id="f-20">ABBV</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-21">NYSE</dei:SecurityExchangeName>
    <dei:SecurityExchangeName contextRef="c-3" id="f-22">CHX</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-4" id="f-23">1.375% Senior Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-4" id="f-24">ABBV24</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-4" id="f-25">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-5" id="f-26">1.250% Senior Notes due 2024</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-5" id="f-27">ABBV24B</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-5" id="f-28">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-6" id="f-29">0.750% Senior Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-6" id="f-30">ABBV27</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-6" id="f-31">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-7" id="f-32">2.125% Senior Notes due 2028</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-7" id="f-33">ABBV28</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-7" id="f-34">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-8" id="f-35">2.625% Senior Notes due 2028</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-8" id="f-36">ABBV28B</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-8" id="f-37">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-9" id="f-38">2.125% Senior Notes due 2029</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-9" id="f-39">ABBV29</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-9" id="f-40">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-10" id="f-41">1.250% Senior Notes due 2031</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-10" id="f-42">ABBV31</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-10" id="f-43">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-44">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
